Immune Response in Lung Cancer

Lithuanian University of Health Sciences1 site in 1 country100 target enrollmentSeptember 2012

ConditionsLung Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Lung Cancer
Sponsor: Lithuanian University of Health Sciences
Enrollment: 100
Locations: 1
Primary Endpoint: progression-free survival
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study is designed to evaluate the importance of the immune cells localization (distribution) between malignant tumor islets and surrounding stroma and to investigate the associations between these immune cells as well as cytokines and clinicopathological and prognostic factors of non-small cell lung cancer (NSCLC) patients.

Registry

clinicaltrials.gov

Start Date

September 2012

End Date

March 2016

Last Updated

8 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Lithuanian University of Health Sciences

Responsible Party

Principal Investigator

Marius Zemaitis

Assoc. Professor

Lithuanian University of Health Sciences

Eligibility Criteria

Inclusion Criteria

•Eastern Cooperative Oncology Group (ECOG) score of 0-1
•Patients with histologically documented non-small cell lung cancer
•Control group - patients without non-small cell lung cancer
•Written (signed) Informed Consent to participate in the study

Exclusion Criteria

•Any other malignancies within 5 years
•Any unstable systemic disease (including active infections, significant cardiovascular disease)
•Prior chemotherapy or radiotherapy
•Autoimmune disease
•Nursing or pregnant women